Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis

Table 2 Risk factors for ^anon-compliance to bisphosphonates in patients with rheumatoid arthritis

Variables	Univariable		Multivariable
Variables	OR (95% CI)	p value	^bOR (95% CI)	p value
Dosing frequency weekly vs. monthly BPs	2.42 (1.57–3.73)	<0.001	2.48 (1.59–3.89)	<0.001
Seropositive RA	0.43 (0.26–0.73)	0.002	0.51 (0.29–0.89)	0.019
Disease duration ≥ 24 months	0.48 (0.31–0.73)	0.001	0.66 (0.41–1.05)	0.077
Calcium /vitamin D supplement	2.01 (1.21–3.34)	0.007	1.8 (1.04–3.12)	0.037
Previous compression fracture	0.9 (0.42–1.97)	0.8
Reimbursement for BPs	1.15 (0.75–1.15)	0.519	-	-
Age, years	1 (0.99–1.02)	0.632	-	-
Glucocorticoids use	0.79 (0.44–1.42)	0.427
Baseline DEXA	0.68 (0.35–1.29)	0.236
DAS28-ESR	1.05 (0.92–1.19)	0.477

BPs bisphosphonates, RA rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, DAS28-ESR disease activity score assessed using the 28-joint count for swelling and tenderness- erythrocyte sedimentation rate
^aNon-compliance was defined if the 1-year medication possession ratio was less than 0.8
^bEstimated using multivariable backward logistic regression models including dosing frequency of BPs, seropositive RA, disease duration > 24 months, calcium /vitamin D supplement, age and reimbursement for BPs

ISSN: 1471-2474